5,379 Shares in Biogen Inc. $BIIB Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC bought a new position in Biogen Inc. (NASDAQ:BIIB) in the first quarter, HoldingsChannel.com reports. The fund bought 5,379 shares of the biotechnology company’s stock, valued at approximately $1,025,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of Biogen by 2.4% in the first quarter. Bank of America Corp DE now owns 1,156,369 shares of the biotechnology company’s stock worth $211,997,000 after acquiring an additional 27,524 shares during the period. Kentucky Retirement Systems grew its stake in shares of Biogen by 112.6% during the 1st quarter. Kentucky Retirement Systems now owns 19,502 shares of the biotechnology company’s stock valued at $3,575,000 after purchasing an additional 10,331 shares during the period. Bull Harbor Capital LLC bought a new stake in shares of Biogen during the 1st quarter valued at about $931,000. Arkadios Wealth Advisors increased its position in shares of Biogen by 4.5% during the 1st quarter. Arkadios Wealth Advisors now owns 4,781 shares of the biotechnology company’s stock valued at $877,000 after purchasing an additional 206 shares during the last quarter. Finally, Encore Global Management LP bought a new position in shares of Biogen in the 1st quarter worth approximately $92,000. 87.93% of the stock is owned by institutional investors.

Biogen Stock Down 0.9%

Shares of BIIB stock opened at $206.63 on Thursday. The company has a market capitalization of $30.53 billion, a price-to-earnings ratio of 36.57, a PEG ratio of 6.44 and a beta of 0.17. Biogen Inc. has a one year low of $127.00 and a one year high of $219.72. The company’s fifty day moving average price is $201.89 and its 200-day moving average price is $191.35. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the prior year, the firm posted $5.47 EPS. Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts expect that Biogen Inc. will post 12.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on BIIB. Wedbush upped their target price on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. UBS Group upped their price objective on Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Sanford C. Bernstein decreased their target price on Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and lifted their target price for the company from $190.00 to $235.00 in a research report on Monday, July 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Biogen presently has an average rating of “Moderate Buy” and an average price target of $224.61.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.